Brigatinib (BioDeep_00000176821)
human metabolite blood metabolite
代谢物信息卡片
5-chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine
化学式: C29H39ClN7O2P (583.2591233999999)
中文名称: 布格替尼
谱图信息:
最多检出来源 Homo sapiens(blood) 10.71%
分子结构信息
SMILES: CN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3)NC4=NC=C(C(=N4)NC5=CC=CC=C5P(=O)(C)C)Cl)OC
InChI: InChI=1S/C29H39ClN7O2P/c1-35-15-17-37(18-16-35)21-11-13-36(14-12-21)22-9-10-24(26(19-22)39-2)33-29-31-20-23(30)28(34-29)32-25-7-5-6-8-27(25)40(3,4)38/h5-10,19-21H,11-18H2,1-4H3,(H2,31,32,33,34)
描述信息
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01ED - Anaplastic lymphoma kinase (alk) inhibitors
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C141136 - ALK Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
同义名列表
数据库引用编号
6 个数据库交叉引用编号
- PubChem: 68165256
- HMDB: HMDB0249380
- DrugBank: DB12267
- ChEMBL: CHEMBL3545311
- Wikipedia: Brigatinib
- CAS: 1197953-54-0
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Yuyao Luo, Zhe Zhang, XuanZhu Guo, Xuemei Tang, Sijie Li, Guotao Gong, Shun Gao, Yan Zhang, Sheng Lin. Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: Systematic review and network meta-analysis.
Lung cancer (Amsterdam, Netherlands).
2023 Aug; 184(?):107319. doi:
10.1016/j.lungcan.2023.107319. [PMID: 37597303] - Bei Zheng, Hong Jiang, Wenjuan Yang, Ying Li, Bingqing Liang, Jun Zhu, Nanmei Chen, Miao Chen, Meiling Zhang. A Bayesian network meta-analysis of ALK inhibitor treatments in patients with ALK-positive non-small cell lung cancer.
Cancer medicine.
2023 08; 12(15):15983-15997. doi:
10.1002/cam4.6241. [PMID: 37334877] - Yang Zhou, Shuang Xiang, Fang Yang, Xiaoyun Lu. Targeting Gatekeeper Mutations for Kinase Drug Discovery.
Journal of medicinal chemistry.
2022 12; 65(23):15540-15558. doi:
10.1021/acs.jmedchem.2c01361. [PMID: 36395392] - Hao Chen, Mengzhen Lai, Tao Zhang, Yuqing Chen, Linjiang Tong, Sujie Zhu, Yang Zhou, Xiaomei Ren, Jian Ding, Hua Xie, Xiaoyun Lu, Ke Ding. Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations.
Journal of medicinal chemistry.
2022 05; 65(9):6840-6858. doi:
10.1021/acs.jmedchem.2c00168. [PMID: 35446588] - Shan Li, Tao Zhang, Su-Jie Zhu, Chong Lei, Mengzhen Lai, Lijie Peng, Linjiang Tong, Zilu Pang, Xiaoyun Lu, Jian Ding, Xiaomei Ren, Cai-Hong Yun, Hua Xie, Ke Ding. Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFRT790M/C797S Mutants.
ACS medicinal chemistry letters.
2022 Feb; 13(2):196-202. doi:
10.1021/acsmedchemlett.1c00555. [PMID: 35178175] - Hiroto Kataoka, Tetsuya Saita, Asuki Oka, Momoka Yamada, Masashi Shin. An Indirect Competitive Enzyme-Linked Immunosorbent Assay for the Determination of Brigatinib and Gilteritinib Using a Specific Polyclonal Antibody.
Biological & pharmaceutical bulletin.
2022; 45(7):904-909. doi:
10.1248/bpb.b22-00166. [PMID: 35786598] - D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James C H Yang, Ji-Youn Han, Maximilian J Hochmair, Ki Hyeong Lee, Angelo Delmonte, Maria Rosario Garcia Campelo, Dong-Wan Kim, Frank Griesinger, Enriqueta Felip, Raffaele Califano, Alexander I Spira, Scott N Gettinger, Marcello Tiseo, Huamao M Lin, Yuyin Liu, Florin Vranceanu, Huifeng Niu, Pingkuan Zhang, Sanjay Popat. Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2021 12; 16(12):2091-2108. doi:
10.1016/j.jtho.2021.07.035. [PMID: 34537440] - Hao-Chuan Ma, Yi-Hong Liu, Kai-Lin Ding, Yu-Feng Liu, Wen-Jie Zhao, Yan-Juan Zhu, Xue-Song Chang, Ya-Dong Chen, Zhen-Zhen Xiao, Ya-Ya Yu, Rui Zhou, Hai-Bo Zhang. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.
BMC cancer.
2021 Nov; 21(1):1278. doi:
10.1186/s12885-021-08977-0. [PMID: 34836510] - Neeraj Gupta, Michael J Hanley, David Kerstein, Meera Tugnait, Narayana Narasimhan, Thomas C Marbury, Karthik Venkatakrishnan. Effect of severe renal impairment on the pharmacokinetics of brigatinib.
Investigational new drugs.
2021 10; 39(5):1306-1314. doi:
10.1007/s10637-021-01095-5. [PMID: 33742299] - Halah S Almutairi, Mona M AlShehri, Mohammed M Alanazi, Ibrahim A Darwish, Hany W Darwish. Novel spectrofluorimetric determination of brigatinib in bulk powder and human urine samples via ion-pair complex formation using eosin Y.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
2021 Mar; 249(?):119210. doi:
10.1016/j.saa.2020.119210. [PMID: 33234480] - Neeraj Gupta, Xiaohui Wang, Elliot Offman, Marita Prohn, Narayana Narasimhan, David Kerstein, Michael J Hanley, Karthik Venkatakrishnan. Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer.
Clinical pharmacokinetics.
2021 02; 60(2):235-247. doi:
10.1007/s40262-020-00929-4. [PMID: 32816246] - Jie He, Zhihui Zhou, Xin Sun, Zunhua Yang, Pengwu Zheng, Shan Xu, Wufu Zhu. The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation.
European journal of medicinal chemistry.
2021 Jan; 210(?):112995. doi:
10.1016/j.ejmech.2020.112995. [PMID: 33243531] - Mohammed Muqtader Ahmed, Farhat Fatima, Md Khalid Anwer, Mohammed F Aldawsari, Yasser Saud M Alsaidan, Suliman Abdulaziz Alfaiz, Anzarul Haque, Alanazi Az, Khalid Alhazzani. Development and characterization of Brigatinib loaded solid lipid nanoparticles: In-vitro cytotoxicity against human carcinoma A549 lung cell lines.
Chemistry and physics of lipids.
2020 11; 233(?):105003. doi:
10.1016/j.chemphyslip.2020.105003. [PMID: 33096096] - D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James C H Yang, Ji-Youn Han, Maximilian J Hochmair, Ki Hyeong Lee, Angelo Delmonte, Maria Rosario García Campelo, Dong-Wan Kim, Frank Griesinger, Enriqueta Felip, Raffaele Califano, Alexander Spira, Scott N Gettinger, Marcello Tiseo, Huamao M Lin, Neeraj Gupta, Michael J Hanley, Quanhong Ni, Pingkuan Zhang, Sanjay Popat. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2020 11; 38(31):3592-3603. doi:
10.1200/jco.20.00505. [PMID: 32780660] - Xiaoyun Lu, Jeff B Smaill, Ke Ding. Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations.
Journal of medicinal chemistry.
2020 10; 63(19):10726-10741. doi:
10.1021/acs.jmedchem.0c00507. [PMID: 32432477] - Meera Tugnait, Neeraj Gupta, Michael J Hanley, Daryl Sonnichsen, David Kerstein, David J Dorer, Karthik Venkatakrishnan, Narayana Narasimhan. Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
Clinical pharmacology in drug development.
2020 02; 9(2):214-223. doi:
10.1002/cpdd.723. [PMID: 31287236] - Jiayi Shen, Tao Zhang, Su-Jie Zhu, Min Sun, Linjiang Tong, Mengzhen Lai, Rong Zhang, Wei Xu, Ruibo Wu, Jian Ding, Cai-Hong Yun, Hua Xie, Xiaoyun Lu, Ke Ding. Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S).
Journal of medicinal chemistry.
2019 08; 62(15):7302-7308. doi:
10.1021/acs.jmedchem.9b00576. [PMID: 31298540] - Meera Tugnait, Neeraj Gupta, Michael J Hanley, Karthik Venkatakrishnan, Daryl Sonnichsen, David Kerstein, David J Dorer, Narayana Narasimhan. The Effect of a High-Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
Clinical pharmacology in drug development.
2019 08; 8(6):734-741. doi:
10.1002/cpdd.641. [PMID: 30570839] - Takeshi Hirota, Shota Muraki, Ichiro Ieiri. Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer.
Clinical pharmacokinetics.
2019 04; 58(4):403-420. doi:
10.1007/s40262-018-0689-7. [PMID: 29915924] - Rolf W Sparidans, Wenlong Li, Alfred H Schinkel, Jan H M Schellens, Jos H Beijnen. Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates.
Journal of pharmaceutical and biomedical analysis.
2018 Nov; 161(?):136-143. doi:
10.1016/j.jpba.2018.08.038. [PMID: 30149189] - Xiaoyun Lu, Tao Zhang, Su-Jie Zhu, Qiuju Xun, Lingjiang Tong, Xianglong Hu, Yan Li, Shingpan Chan, Yi Su, Yiming Sun, Yi Chen, Jian Ding, Cai-Hong Yun, Hua Xie, Ke Ding. Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy.
ACS medicinal chemistry letters.
2018 Nov; 9(11):1123-1127. doi:
10.1021/acsmedchemlett.8b00373. [PMID: 30429956] - Wenlong Li, Rolf W Sparidans, Yaogeng Wang, Maria C Lebre, Jos H Beijnen, Alfred H Schinkel. P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability.
Pharmacological research.
2018 11; 137(?):47-55. doi:
10.1016/j.phrs.2018.09.020. [PMID: 30253203] - Hany W Darwish, Adnan A Kadi, Mohamed W Attwa, Halah S Almutairi. Investigation of metabolic stability of the novel ALK inhibitor brigatinib by liquid chromatography tandem mass spectrometry.
Clinica chimica acta; international journal of clinical chemistry.
2018 May; 480(?):180-185. doi:
10.1016/j.cca.2018.02.016. [PMID: 29458050] - Jian Wen, Susu Bao, Yaoyao Cai, Bowen Zhang, Rongrong Wang, Chenchen Wang, Guoxin Hu. A reliable and stable method for determination of brigatinib in rat plasma by UPLC-MS/MS: Application to a pharmacokinetic study.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2017 Nov; 1068-1069(?):84-89. doi:
10.1016/j.jchromb.2017.10.007. [PMID: 29032042]